The three largest PBMs in the United States still control roughly 80 percent of prescription volume. That number has not meaningfully moved in three years. What has moved is the pressure surrounding it. The FTC's interim reports, state-level pass-through legislation in more than 20 states, plan sponsor frustration with rebate economics, and the steady rise of transparent challengers like Capital Rx, Navitus, SmithRx, and RxBenefits have pushed the segment into the most structurally unsettled period it has seen since the Caremark-CVS merger closed.
For operators inside this market, the strategic question is no longer whether the model changes. It is how fast, how unevenly, and which roles absorb the impact first.
This is the first edition of The Market Signal, a weekly briefing built for leaders operating inside PBMs, healthcare BPOs, shared service centers, call centers, and payment integrity. Each edition reads one vertical clearly, names the moving pieces, and gives you a usable read on where the hiring and talent market is actually going. This week, PBMs.
The Midweek Pulse Check
Before the read, three questions worth answering honestly if you lead inside a PBM, a health plan, or a vendor selling into PBM operations.
If pass-through pricing becomes the federal default in the next 18 months, how does your operating model absorb it? The organizations that have already modeled this transition are moving on capabilities now. The ones still treating it as a regulatory scenario will be reorganizing under pressure in the back half of the year.
Which functions in your organization still assume scale protects them? Formulary operations, rebate contracting, and prior authorization have historically traded on volume. Each of those is being reshaped by transparent competitors who do not rely on the same economics and by AI tooling that flattens the cost curve.
Where is your bench thin enough that one departure changes the trajectory of a major initiative? In PBM operations, the single-threaded roles are almost always the clinical pharmacist leadership, the senior trade relations talent, and the implementation managers who know both the system and the client. That is where the market is hottest right now.
The Shift the Market Is Making
For 15 years, the defining question in the PBM market was scale. Whoever consolidated faster, negotiated harder, and owned more of the vertical stack won. That thesis is still true at the top of the market, but underneath it, a second market is forming that does not share the same assumptions.
The transparent PBM segment, the health plan build-in-house movement, and the direct contracting arrangements between employers and specialty pharmacies are all pulling prescription volume away from traditional rebate economics. The movement is not yet large enough to reshape the top three, but it is large enough to reshape hiring demand. The talent going into Capital Rx, Navitus, SmithRx, RxBenefits, and the health-plan-owned PBM operations is often the same talent previously sitting inside the top three, and the compensation premium to move is real.
The strategic read for anyone operating in this market is that you are competing for talent in two directions at once. Against the incumbents for stability and brand. Against the challengers for upside, flexibility, and the chance to build something before it calcifies.
The Moving Pieces You Should Be Tracking
01The Regulatory Clock
The FTC's second interim report, the DOJ scrutiny of vertical integration, and the continued push for pass-through pricing at the state level are not independent events. They are the same pressure taking different forms.
What to watch: the states that have already passed spread pricing bans (Ohio, West Virginia, Kentucky, Louisiana, Arkansas, and a growing list) are becoming the real-world test case for what a reformed PBM model looks like operationally. The cost-to-serve, the margin compression, and the staffing model for transparent operations are all being built and observed in real time by plan sponsors who will bring those expectations into every future RFP.
What it means for talent: operations leaders who can run a transparent model without the cushion of spread revenue are the most recruited profile in the segment. Finance, analytics, and client-facing account management talent with transparent PBM experience is trading at a 10 to 20 percent compensation premium right now.
02Clinical Pharmacist Supply
The national pharmacist labor market softened in 2024 and 2025, with retail closures at CVS, Walgreens, and Rite Aid pushing thousands of PharmD professionals into the search. That loosened the supply side meaningfully for clinical pharmacist roles inside PBMs, health plans, and specialty.
What to watch: the softening is not uniform. Prior authorization clinical pharmacists and formulary management pharmacists are still tight in most metros. Specialty pharmacy clinical leadership is still very tight. The easing is concentrated in general clinical review and MTM roles.
What it means for talent: PBM operators who waited on hiring through 2024 now have a real window through Q2. After that, the retail absorption catches up and the market tightens again.
03Prior Authorization Automation
The PA function is where AI and rules-based automation are moving fastest inside PBM operations. Every major PBM is running some form of automated PA pilot. The transparent challengers are often further along because they built their stacks from scratch in the last five years.
What to watch: the bottleneck is not the technology. It is the clinical governance and appeals management wrapped around the automation. That work sits with senior clinical pharmacists, appeals managers, and medical policy teams. Demand for those profiles has actually risen as automation has expanded, because someone has to own the cases the system kicks out.
What it means for talent: entry-level PA coordinator roles are flattening. Mid to senior clinical oversight, appeals leadership, and medical policy talent is the strongest segment of the PBM hiring market right now.
04Trade Relations and Rebate Talent
The most undervalued talent segment in this market is senior trade relations and rebate contracting leadership. As the rebate model gets pressured publicly, the operators who actually understand how to restructure those contracts in a transparent environment become the profile everyone wants and no one can find.
What to watch: the top PBMs have been quietly building retention packages for trade and rebate leadership. The challengers are aggressively recruiting that same population.
What it means for talent: if you have a senior trade or rebate leader sitting in a 15-year tenure role, they are on a short list at three competitors right now. Retention conversations this quarter will cost less than replacement conversations in Q3.
05Implementation and Client Services
The unsexy truth of the PBM market is that the segment most consistently tight across both incumbents and challengers is implementation management and senior client services. Plan sponsor churn, the growth of transparent PBMs, and the increasing complexity of carve-out arrangements have made implementation the single most load-bearing function in the segment.
What to watch: implementation talent tends to be regional and relationship-heavy. Losing one senior implementation manager often means losing the downstream renewal with the clients they were anchoring.
What it means for talent: this is the function where retention needs to be treated as a client-retention issue, not an HR issue. The cost of a bad hire or a departed senior IM is measured in plan sponsor relationships, not in salary dollars.
What to Watch This Quarter
The FTC's follow-up activity, Capital Rx's continued employer wins, and any movement on the federal pass-through pricing bill working through committee. If any one of those lands, the talent market responds within 30 days. The operators who track signals to moves, rather than moves to signals, are the ones who will hire ahead of the curve rather than at the peak of it.
Common Misreads
Assuming the top three are locked in
The top three are still dominant, but the hiring market tells a different story than the market share chart. Senior talent is increasingly willing to move out of the incumbents for smaller, transparent operators with clearer upside. The brand premium has softened.
Treating the softer pharmacist market as a permanent loosening
The retail-driven supply bump is temporary. The PBM operators who hire into that window through Q2 will look prescient. The ones who wait until Q4 will find themselves competing with both the challengers and a tightening supply side.
Underinvesting in medical policy and appeals leadership
Automation does not reduce the need for medical policy and appeals talent. It concentrates it. The organizations that pulled back on those functions in the last 18 months are the ones rebuilding them now at a premium.
Ignoring the carve-out wave from large employers
The number of self-insured employers carving specialty out of their PBM arrangements is not marginal anymore. That flow is reshaping the specialty pharmacy talent market and creating hiring demand that does not show up in the traditional PBM dashboards.
Your Strategy Through the Quarter
If you lead talent inside a top-three PBM
Audit your senior trade, clinical, and implementation bench this month. Identify the three to five individuals whose departure would cost you a client or a program. Build retention conversations now, not after the counter-offer arrives. The cost of a retention package in Q2 is a fraction of the cost of a replacement search in Q3 plus the revenue impact of a lost plan sponsor.
If you lead talent inside a transparent or challenger PBM
This is the window to hire senior incumbents who are open to moving. The softening pharmacist market, the regulatory pressure on the top three, and the compensation premium you can offer as a challenger create a short alignment of conditions. That window closes as the market absorbs the retail bump and the incumbents tighten retention.
If you are a plan sponsor, broker, or health plan evaluating PBM partners
The diligence question that separates the serious operators from the marketing-led ones is staffing model. Ask how they handle clinical pharmacist review, PA adjudication, medical policy, and appeals. The answer tells you more about the quality of the service than any pricing page will.
The Operator's Read
The PBM market is entering the phase where talent decisions become more strategic than contract decisions. The organizations that understand that shift and move on it in the next two quarters will hold a durable advantage through the rest of the decade. The ones that wait for the next regulatory event to force their hand will be reorganizing under pressure instead of building under clarity.
The market is still moving. The window to hire ahead of the curve is open right now.
The PBM Talent Market Map
A one-page view of where PBM talent is moving, where the hot roles are, and what the compensation premium looks like by segment. Free.